De Motu Cordis Founder and CMO, Professor John Fraser Awarded Order of Australia
February 18, 2025
De Motu Cordis would like to congratulate Professor John Fraser, who has been named as an Officer of the Order of Australia (AO).
Professor John Fraser, from UQ’s Institute for Molecular Bioscience, has been appointed an Officer of the Order of Australia (AO) for his distinguished service to medicine as an intensive care physician and surgeon, and to global critical care research.
Professor Fraser received his PhD from UQ in 2010 and is the Director of Intensive Care Unit at St Andrew’s War Memorial Hospital in Brisbane and Chief Medical Officer at De Motu Cordis.
He also founded the Critical Care Research Group (CCRG) two decades ago.
With a global network spanning more than 60 countries, CCRG is a world leader in developing technologies and interventions to improve outcomes for critically ill patients – encompassing clinical, pre-clinical and engineering research.
The group is based at Australia’s largest cardiac hospital, The Prince Charles Hospital, and investigates better ways to support patients with heart and lung failure.
His work includes refining a method of keeping a heart “alive” outside the body for 12 hours – increasing the availability of donors’ hearts, a revolutionary practice that has helped people around the world.
“I am equal parts humbled and honoured to receive this huge accolade from my adoptive homeland of Australia,” Professor Fraser said.
“It represents not just my efforts, but the efforts of my many mentors, collaborators and team members I have had the good fortune to work with and learn from.
“None of it would have been possible without the guidance of my parents nor the love and support of my 5 wonderful kids.”
Story from UQ community recognised in Australia Day honours – UQ News – The University of Queensland, Australia
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
